In lung cancer, erlotinib has been shown to be effective in patients with or without EGFR mutations, but appears to be more effective in patients with EGFR mutations.52, 53 However, erlotinib alone or in combination with conventional adjuvant therapies has not shown to represent a major success for GBM treatment.54 Besides, Try1068‐phosphrylated EGFR is also shown to be a target of erlotinib.55 In this study, we used erlotinib to block EGFR and the result showed that MYST1 overexpression‐promoted cell proliferation and EGFR activation were rescued after EGFR blockade (Figure 7). This evidence concerns the gene KAT8 and lung carcinoma.